Anuh Pharma Ltd receives WHO PQ approval for Amodiaquine Hydrochloride USP

Anuh Pharma Limited ("the Company") has received the World Health Organization (WHO) Prequalification (WHO PQ) approval for the following Active Pharmaceutical Ingredient (API):

Product Name - Amodiaquine Hydrochloride USP (Amodiaquine HCl USP)
Drug Category - Anti-Malarial API (Active Pharmaceutical Ingredient)
Pharmacopoeial Standard - United States Pharmacopeia (USP)
Approval Body - World Health Organization (WHO) - Prequalification Programme
Approval Type - WHO Prequalification of Medicines Programme - Active Pharmaceutical Ingredient
Applicable Market - International markets including WHO-procured and donor-funded programmes

Amodiaquine Hydrochloride is an essential medicine listed by the WHO and widely used in combination therapies for the treatment of uncomplicated Plasmodium falciparum malaria. This approval further consolidates Anuh Pharma's position as a preferred API supplier for global anti-malarial programmes.

Shares of ANUH PHARMA LTD. was last trading in BSE at Rs. 79.70 as compared to the previous close of Rs. 81.99. The total number of shares traded during the day was 5152 in over 350 trades.

The stock hit an intraday high of Rs. 83.75 and intraday low of 77.94. The net turnover during the day was Rs. 416139.00.

Source : Equity Bulls

Keywords

ANUHPHARMA INE489G01022 Pharmaceuticals WHO Prequalification Approval API